Abstract
ObjectiveThe aim of this study is to investigate the effect of irisin on leukemia inhibitory factor (LIF) and integrin αvβ3 in implantation failure uterus.MethodsEarly pregnant rats were randomly divided into normal group (N), mifepristone treated group (M), irisin group (I) and progestin group (P). The implantation failure model was established using mifepristone. Second, we evaluated the average number of embryos and detected the expression of LIF and integrin αvβ3 protein and mRNA in endometrium.ResultsCompared with group M, the average number of embryos was significantly higher in group N, P and I, the expression of LIF and integrin αvβ3 in endometrium was significantly higher in group N, P and I.ConclusionIrisin could improve the poor receptive state of endometrium by promoting LIF and integrin αvβ3 secretion to improve blastocyst implantation in rats of implantation failure.
Highlights
Irisin, a newly discovered myokine, is released from the muscle immediately after exercise
Many subsequent studies have investigated a potential role in metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), lipid metabolism
13.86 ± 4.75b arepresents that there is significant difference when group M is compared with group N (P < 0.05) brepresents that there is significant difference when group I and P is compared with group M (P < 0.05)
Summary
A newly discovered myokine, is released from the muscle immediately after exercise. It is secreted from fibronectin type III domain containing 5 (FNDC5) after the cleavage of its extracellular protein [1]. It drives brown-fat-like conversion of white adipose tissues (WAT) and has been suggested to improve metabolic and glucose homeostasis [2]. Irisin has been the subject of many studies due to its physiopathyological role. Many subsequent studies have investigated a potential role in metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), lipid metabolism
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
